

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 16 January 2021

Situation Report No. 215 - Kingdom of Bahrain

17th of January, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	92,506,811	2,001,773	5,309,701	127,388
New	2,120,644 in 3 days	46,240 in 3 days	84,715 in 3 days	1,231 in 3 days


Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	97,268	94,039	358	2,871	18	2,541,873
New	798 in 3 days	879 in 3 days	2 in 3 days	-	-	34,628 in 3 days


HIGHLIGHTS

- The mortality were a 61 and 71 year old Male Bahraini Citizens.
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 16 January 2021 is 137,159.
- MOH announced that COVID-19 Mobile Vaccination Units are being rolled out across the kingdom for the elderly and people with special needs.
- MOH urged people who have taken the first dose of COVID-19 vaccine to schedule to receive the second dose in 21 days.
- GCC health Undersecretaries held their 13th Meeting remotely which focusing on COVID-19 developments.
- MOH indicated that Pfizer-BioNTech has rescheduled vaccine shipments to the Kingdom.
- Three generations from the same family were infected with the coronavirus after an elder woman had tested positive.
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO :Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun assay; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: The push for a COVID-19 vaccine; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place bo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Draft landscape of COVID-19 candidate vaccines; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.


Number of New Cases



Total Number of Cases



Number of New Deaths



IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=6d49a7e_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID19 for pregnant women and their babies: <https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/29v5d5r>
- WHO :Emergency Global Supply Chain System(COVID-19) catalogue: [https://www.who.int/publications/i/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/i/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmun assays: bit.ly/2H0JyVF
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/20wVWQ>
- WHO: The push for COVID-19 vaccine: <https://bit.ly/3m53HAA>
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/3panK5M>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: https://www.who.int/publications/i/item/WHO-2019-ncov-hcf_assessment-products-2020.1
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/i/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector>
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/i/item/9789210012747>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/i/item/1066533753>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: https://www.who.int/publications/i/item/WHO-2019-ncov-Policy_Brief-EUD_placebo-controlled_vaccine_trials-2020.1
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: https://www.who.int/publications/i/item/WHO-2019-ncov-Risk-based_international_travel-Assessment_tool-2020.1
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/i/item/9789210018440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: https://www.who.int/publications/i/item/WHO-2019-ncov-vaccines-SAGE_recommendation-BNT162b2-2021.1
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Draft landscape of COVID-19 candidate vaccines: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: https://www.who.int/publications/i/item/WHO-2019-ncov-essential_health_services-monitoring-2021.1
- WHO: Background document on mRNA vaccine BNT 162b2 (Pfizer-BioNTech) against COVID-19: [https://www.who.int/publications/i/item/backgrounddocument-on-mrna-vaccine-bnt162b2-\(pfizer-biotech\)-against-covid-19](https://www.who.int/publications/i/item/backgrounddocument-on-mrna-vaccine-bnt162b2-(pfizer-biotech)-against-covid-19)

IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAI5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh